Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation.
OBJECTIVE
To determine the effect of particle size of superparamagnetic iron oxide (SPIO) contrast agents on magnetic resonance angiography of the portal venous system.


METHODS
We studied eight beagle dogs by a T1-weighted 3D turbo-gradient echo magnetic resonance (MR) angiography sequence (TE 4 milliseconds, TR 11 milliseconds, flip angle 25 degrees, coronal imaging plane) before and after administration of either Resovist (SHU555A), a superparamagnetic iron oxide contrast agent with a mean particle size of 60 nm and a relaxivity ratio R2/R1 of approximately 7, or a new ultrasmall superparamagnetic iron oxide (USPIO) contrast agent with a mean particle size of approximately 20 nm and a R2/R1 ratio of approximately 2. Images were acquired on a 1.5-T MR body scanner. Both agents were injected as a peripheral bolus of 40 mumol Fe/kg body weight. Repeated scans were acquired before, immediately after, and 10, 20, 30, and 40 minutes after administration of the agent.


RESULTS
After administration of Resovist, portal venous signal increased to 237% of control immediately after injection, while hepatic parenchymal signal intensity decreased to 86% of control. The maximal CNR increase to 177% was achieved immediately after injection of the agent. After USPIO, portal venous signal increased to 401% of the precontrast value immediately after injection, while hepatic parenchymal signal intensity also increased to 131% of control at this time. Hepatic signal then decreased progressively to 49% of control after 40 minutes. The maximal CNR increase to 326% was achieved 10 minutes after injection of the agent.


CONCLUSIONS
It is concluded that superparamagnetic iron oxide particles of different sizes have different R2/R1 ratios and, consequently, different mechanisms of contrast improvement in T1-weighted portal MR angiograms.
Knollmann
F D
FD
Strahlenklinik und Poliklinik Charité, Virchow-Klinikum, Medizinische Fakultät der Humboldt, Universität zu Berlin, Germany.
Böck
J C
JC
Rautenberg
K
K
Beier
J
J
Ebert
W
W
Felix
R
R
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage*; D003911:Dextrans; D004285:Dogs; D052203:Ferrosoferric Oxide; D005500:Follow-Up Studies; D007089:Image Enhancement / Q000379:methods*; D007262:Infusions, Intravenous; D007501:Iron / Q000008:administration & dosage; D018810:Magnetic Resonance Angiography; D058185:Magnetite Nanoparticles; D010087:Oxides / Q000008:administration & dosage; D011168:Portal System / Q000033:anatomy & histology*; D013535:Suspensions
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D013535:Suspensions; C097921:ferumoxtran-10; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide